| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T10 |
0-183 |
Sentence |
denotes |
In addition to current approaches such as glucocorticoids for treating advanced COVID-19 patients, there may be other drug combinations that could be helpful, some being bifunctional. |
| T11 |
184-478 |
Sentence |
denotes |
As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors. |
| T12 |
479-635 |
Sentence |
denotes |
Another bifunctional drug was formulated to antagonize the receptors for platelet-activating factor and histamine, and mast cell secretion-blocking effects. |
| T13 |
636-780 |
Sentence |
denotes |
A third anti-inflammatory drug combined an antagonist for the thromboxane receptor and cysteinyl-leukotriene antagonists into the same molecule. |
| T14 |
781-1027 |
Sentence |
denotes |
A bifunctional antibody construct was also developed for IL-4 and IL-13 to reduce the IL-4-dependent rise in serum IgE and IL-13-dependent airway hyperresponsiveness, lung inflammation, mucin gene expression and serum chitinase responses in mice. |
| T15 |
1028-1192 |
Sentence |
denotes |
In this vein, bifunctional immunotherapeutic approaches could be developed for treatment of the cytokine storm in COVID-19 patients with ARDS at high risk of death. |
| T16 |
1193-1540 |
Sentence |
denotes |
Proven and developing therapies that downregulate receptors for IL-1β, TNF-α, IL-6 and IL-2 as well as those which block macrophage migration inhibitory factor (MIF) and its homolog MIF2 through CD74 and potentially CXCR2&4 for MIF are all potential inhibitors of cytokine storm effects and could be combined or designed for bifunctional activity. |
